Dallah Healthcare (4004.SR) Earnings Analysis

Dallah Healthcare (4004.SR) next reports earnings on 2026-08-10, consensus EPS 1.27 SAR. Last quarter (2026-05-10) it missed with EPS 0.84 SAR vs 1.32 SAR est (-36.4%). It has beaten estimates in 6/8 recent quarters (75%). Trailing P/E 22.88.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 4004.SR next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate1.27 SAR
Revenue estimate1.16B

4004.SR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-100.84 SAR1.32 SAR-36.4%Miss
2026-03-041.61 SAR1.28 SAR+25.8%Beat
2025-11-031.4 SAR1.08 SAR+29.6%Beat
2025-08-041.23 SAR1.09 SAR+12.8%Beat
2025-05-121.59 SAR1.21 SAR+31.4%Beat
2025-03-051.17 SAR1.26 SAR-7.1%Miss
2024-11-101.29 SAR1.23 SAR+4.9%Beat
2024-08-051.15 SAR0.84 SAR+36.9%Beat

Beat rate: 6/8 (75%) over reported quarters with consensus data.

4004.SR valuation and analyst view

Trailing P/E22.88
Trailing EPS4.648 SAR
Price / book2.59
Dividend yield2.37%
Market cap10.60B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Dallah Healthcare (4004.SR)'s next earnings date?

Dallah Healthcare is next scheduled to report on 2026-08-10, with a consensus EPS estimate of 1.27 SAR and revenue estimate of 1.16B.

Did 4004.SR beat earnings last quarter?

In its 2026-05-10 report, 4004.SR posted EPS of 0.84 SAR versus a 1.32 SAR estimate — a miss of 36.4%.

What is 4004.SR's earnings track record?

Over the last 8 reported quarters with consensus data, 4004.SR beat estimates 6 times (75%).

What is 4004.SR's current P/E ratio and EPS?

4004.SR trades at a trailing P/E of 22.88 on trailing EPS of 4.648042944175553 SAR.

What do analysts rate 4004.SR?

4004.SR has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.